AbbVie Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Earnings Per Share (EPS):: $3.65, exceeding guidance by $0.06.

Total Net Revenues:: Nearly $17 billion, up 10.2% year-over-year, beating expectations by $300 million.

Adjusted Gross Margin:: 84.7% of sales.

Adjusted R&D Expense:: 13.6% of sales.

Adjusted SG&A Expense:: 21% of sales.

Adjusted Operating Margin:: 48.3% of sales.

Net Interest Expense:: $679 million.

Adjusted Tax Rate:: 14.7%.

2Strategic Updates and Business Highlights

Sales Growth:: Strong performance from SKYRIZI, RINVOQ, and the neuroscience portfolio, each growing over 20%.

Immunology Revenue:: $8.8 billion, with SKYRIZI sales at $5.5 billion (up 24%).

Acquisition of Apogee Therapeutics:: Aimed at enhancing AbbVie's immunology portfolio with multiple assets in dermatology and respiratory diseases.

Regulatory Approvals:: Recent approvals for Decnapaz in the U.S. and QLIPTA in Europe, among others, with significant sales potential anticipated.

Pipeline Progress:: Advancements in R&D, including approvals for RINVOQ in vitiligo and alopecia areata, and strong data supporting upcoming launches.

3Forward Guidance and Outlook

Revenue Guidance:: Increased by $300 million to approximately $67.6 billion for the year.

Adjusted EPS Guidance:: Updated to a range of $13.87 to $14.07, reflecting strong performance and anticipated dilution from the Apogee acquisition.

Third Quarter Expectations:: Projected net revenues of approximately $17.2 billion and adjusted EPS between $3.84 and $3.88.

4Bad News, Challenges, or Points of Concern

Decline in HUMIRA Sales:: Down 36.1% to $706 million due to biosimilar competition.

Oncology Performance:: Total oncology revenues declined 2.4%, with IMBRUVICA sales down 29.4% due to pricing pressures.

Market Competition:: Concerns regarding the crowded landscape for new treatments in immunology and oncology, particularly with emerging therapies for conditions like vitiligo and alopecia areata.

Regulatory Risks:: Potential delays or challenges in securing approvals for new therapies and maintaining patent protections.

5Notable Q&A Insights

SKYRIZI Subcutaneous Approval:: Confidence expressed in upcoming FDA approval for subcutaneous formulation, expected to drive sales acceleration.

Competitive Landscape in Immunology:: SKYRIZI's strong positioning despite new entrants, with no significant impact observed from competitor launches.

Tevapadon Launch in Parkinson's Disease:: Anticipated modest initial ramp-up in sales due to Medicare formulary timing, but long-term potential remains strong.

Bretasilocin Differentiation:: Emphasis on the unique safety profile and dosing convenience compared to other psychedelic treatments, with ongoing studies to assess efficacy at higher doses.

Pipeline Management Post-Apogee Acquisition:: No deprioritization of existing assets in atopic dermatitis; all pipeline assets are being advanced concurrently. Overall, AbbVie reported strong financial results and strategic advancements, with a positive outlook for the remainder of 2026, despite facing competitive pressures and challenges in specific therapeutic areas.